Darren Denjay Pan, MD, on Multiple Myeloma: Inflammatory Biomarkers and Outcomes After CAR T-Cell Therapy
2023 ASH
Darren Denjay Pan, MD, of Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, discusses his findings on risk assessment of CAR T-cell therapy for patients with multiple myeloma. Higher fibrinogen and ferritin values at baseline were associated with inferior overall survival after CAR T-cell therapy, even after controlling for tumor burden. Higher baseline absolute lymphocyte count was also associated with higher risk and grade of immune effector cell–associated neurotoxicity syndrome, an important toxicity to consider for patients receiving CAR T (Abstract 92).
Related Videos
The ASCO Post Staff
Pieter Sonneveld, MD, PhD, of the Netherland’s Erasmus MC Cancer Institute, discusses primary results from the Perseus trial, showing that for patients with newly diagnosed multiple myeloma who are eligible for transplantation, the combination of daratumumab plus bortezomib, lenalidomide, and dexamethasone, followed by daratumumab and lenalidomide maintenance, may be a new standard of care (Abstract LBA1).
The ASCO Post Staff
Mikkael A. Sekeres, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, reviews key abstracts from ASH 2023 on treatment of myelofibrosis, chronic lymphocytic leukemia, large B-cell lymphoma, and acute myeloid leukemia (Abstracts 620, 631, 781, 425).
The ASCO Post Staff
Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, discusses phase I/II findings of the BRUIN study on the use of pirtobrutinib after covalent Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The results suggest that continuing BTK pathway inhibition following a covalent BTK inhibitor may be an important sequencing approach to consider in the treatment of CLL/SLL (Abstract 325).
The ASCO Post Staff
William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the phase I/II BRUIN study, which shows encouraging response and overall survival in patients with Richter transformation. Although this condition remains a challenging diagnosis, pirtobrutinib represents a potential treatment option that warrants further investigation, according to Dr. Wierda (Abstract 1737).
The ASCO Post Staff
Jeffrey E. Rubnitz, MD, PhD, of St. Jude Children’s Research Hospital, discusses study findings suggesting that pharmacogenomic differences between Black and White patients should be considered when tailoring induction regimens to improve outcomes of all patients and bridge the racial disparity gap in acute myeloid leukemia treatment (Abstract 386).
